SEC of DCGI recommends emergency use authorisation of Covaxin for children

Monika Yadav New Delhi | Updated on October 12, 2021

Unnamed official says there was a detailed discussion by the committee before giving the authorisation

The Subject Expert Commitee (SEC) of the drug regulator Drugs Controller General of India (DCGI) has recommended emergency use of authorisation (EUA) to Bharat Biotech’s Covaxin for children in the age group of 2–18 years.

“The overall antibody response for the paediatric population is similar to that of the adult population in phase-III efficacy study,” a government official who didn’t wish to be quoted said.

Also see: Covaxin’s policy review completed, technical review coming up: WHO expert group

“There was a detailed discussion by the committee for giving EUA to Bharat Biotech for Covaxin approval for children. After studying all the clinical trial data, the decision was taken,” the official said.

Hyderabad-based Bharat Biotech had presented its proposal for market authorisation of whole virion, inactivated coronavirus vaccine in the age group of 2 to 18 years for restricted use in emergency situation, along with the interim safety and immunogenicity data of phase II and phase III clinical trials conducted in the age group 2–18.

Published on October 12, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.

You May Also Like